| A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis SN Harun, C Wainwright, K Klein, S Hennig Paediatric respiratory reviews 20, 55-66, 2016 | 129 | 2016 |
| PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool J Nyberg, S Ueckert, EA Strömberg, S Hennig, MO Karlsson, AC Hooker Computer methods and programs in biomedicine 108 (2), 789-805, 2012 | 121 | 2012 |
| Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients: Impact of: CYP3A5: Genotype on Starting Dose TK Bergmann, S Hennig, KA Barraclough, NM Isbel, CE Staatz Therapeutic drug monitoring 36 (1), 62-70, 2014 | 101 | 2014 |
| Improved prediction of tacrolimus concentrations early after kidney transplantation using theory‐based pharmacokinetic modelling E Størset, N Holford, S Hennig, TK Bergmann, S Bergan, S Bremer, ... British journal of clinical pharmacology 78 (3), 509-523, 2014 | 88 | 2014 |
| Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis S Hennig, JF Standing, CE Staatz, AH Thomson Clinical pharmacokinetics 52, 289-301, 2013 | 74 | 2013 |
| Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis–a population pharmacokinetic study S Hennig, R Norris, CMJ Kirkpatrick British journal of clinical pharmacology 65 (4), 502-510, 2008 | 68 | 2008 |
| Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients S Hennig, CE Wainwright, SC Bell, H Miller, LE Friberg, BG Charles Clinical pharmacokinetics 45, 1099-1114, 2006 | 65 | 2006 |
| Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients TH Waterhouse, S Redmann, SB Duffull, JA Eccleston Journal of Pharmacokinetics and Pharmacodynamics 32, 521-545, 2005 | 58 | 2005 |
| Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review R Kirubakaran, SL Stocker, S Hennig, RO Day, JE Carland Clinical Pharmacokinetics 59, 1357-1392, 2020 | 56 | 2020 |
| A d‐optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients S Hennig, TH Waterhouse, SC Bell, M France, CE Wainwright, H Miller, ... British journal of clinical pharmacology 63 (4), 438-450, 2007 | 48 | 2007 |
| A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy‐itraconazole concentrations in cystic fibrosis children with allergic … S Redmann, BG Charles Biomedical Chromatography 20 (4), 343-348, 2006 | 45 | 2006 |
| Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy CC Llanos-Paez, S Hennig, CE Staatz Journal of Antimicrobial Chemotherapy 72 (3), 639-667, 2017 | 42 | 2017 |
| Aspergillus and progression of lung disease in children with cystic fibrosis SN Harun, CE Wainwright, K Grimwood, S Hennig Thorax 74 (2), 125-131, 2019 | 41 | 2019 |
| An evaluation of the user‐friendliness of Bayesian forecasting programs in a clinical setting AA Kumar, M Burgard, S Stacey, I Sandaradura, T Lai, C Coorey, ... British Journal of Clinical Pharmacology 85 (10), 2436-2441, 2019 | 38 | 2019 |
| Bayesian estimation of tobramycin exposure in patients with cystic fibrosis MA Barras, D Serisier, S Hennig, K Jess, RLG Norris Antimicrobial agents and chemotherapy 60 (11), 6698-6702, 2016 | 37 | 2016 |
| Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients C Bloomfield, CE Staatz, S Unwin, S Hennig Antimicrobial agents and chemotherapy 60 (6), 3407-3414, 2016 | 36 | 2016 |
| Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients R Lawson, CE Staatz, CJ Fraser, S Hennig Clinical Pharmacokinetics 60, 17-51, 2021 | 35 | 2021 |
| Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis S Hennig, F Holthouse, CE Staatz Clinical Pharmacokinetics 54, 409-421, 2015 | 32 | 2015 |
| Monitoring of tobramycin exposure: what is the best estimation method and sampling time for clinical practice? Y Gao, S Hennig, M Barras Clinical pharmacokinetics 58, 389-399, 2019 | 29 | 2019 |
| Quizzing for success: Evaluation of the impact of feedback quizzes on the experiences and academic performance of undergraduate students in two clinical pharmacokinetics courses S Hennig, CE Staatz, JA Bond, D Leung, J Singleton Currents in Pharmacy Teaching and Learning 11 (7), 742-749, 2019 | 27 | 2019 |
Mats KarlssonUppsala UniversityVerified email at farmaci.uu.se
